This is a Phase 3, randomized, observer-blind study in healthy individuals.

The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2):

As a 30-microgram dose, administered from 1 of 4 manufacturing lots (batches)

As a 20-microgram dose, administered from 1 of the manufacturing lots

As a 2-dose (separated by 21 days) schedule

In people 12 through 50 years of age